SERB Pharmaceuticals en las noticias
Proveedor global de medicamentos raros
Tamtam encontró 17 artículos recientes sobre SERB Pharmaceuticals.
- SERB Applauds Publication of Consensus Statements and Recommendations for Neuroblastoma Care in Pediatric Blood & Cancer
- Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
- SERB Sizes Up €1bn Sales With M&A Savoir Faire
- Hansa licenses Idefirix to SERB for $133m
- Mayer Brown advises SERB Pharmaceuticals on the agreement entered into with Hansa Biopharma AB to acquire European and MENA rights to Idefirix®(imlifidase)
- Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal
- Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
- SERB signs agreement to acquire Idefirix rights for $133.6m
- SERB Pharmaceuticals buys European and MENA rights to kidney transplant drug Idefirix for €115M
- SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
- Hansa Biopharma Signs €115 Million Imlifidase Licensing Agreement with SERB
- SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
- SERB Pharma to acquire European and MENA rights to Idefirix from Hansa
- SERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the US
- Dr Vignesh Rajah
- SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for $412 Million
- Y-Mabs falls to Serb | ApexOnco - Clinical Trials news and analysis
Artículos recopilados por Tamtam y conservados cuando tratan sobre la empresa, del más reciente al más antiguo. Cada uno enlaza con su fuente.
¿Vendes a empresas como SERB Pharmaceuticals?
Tamtam encuentra las empresas que encajan con tu cliente ideal, investiga cada cuenta y te dice a quién contactar y cuándo.
Encontrar empresas similares